This is an aggregated industry headline. Read the full story at FiercePharma →
AbbVie's Skyrizi narrowly slides ahead of J&J's Tremfya in May drug ad spending rankings
May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie's Skyrizi and RInvoq, Johnson & Johnson's Tremfya and more all decreasing their monthly TV ad spend.
By FiercePharma
· Jun 10, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is strugglin…
The WeekFierceBiotech ↗
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease …
The WeekBriefing
Nuvalent’s Jideytro won FDA approval for adults with locally advanced or metastatic ROS1-positive NSCLC after …